<?xml version='1.0' encoding='utf-8'?>
<document id="23701022"><sentence text="Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients."><entity charOffset="32-41" id="DDI-PubMed.23701022.s1.e0" text="ribavirin" /></sentence><sentence text="One-third of all HIV-infected individuals in the United States are estimated to be coinfected with the hepatitis C virus (HCV)" /><sentence text=" Treatment of chronic hepatitis C in patients coinfected with HIV is a complex problem associated with toxicities and drug interactions between HIV antiretrovirals and interferon and ribavirin"><entity charOffset="183-192" id="DDI-PubMed.23701022.s3.e0" text="ribavirin" /></sentence><sentence text=" In recent HCV treatment studies, we observed a previously unreported development of hypophosphatemia in HIV/HCV-coinfected patients treated with interferon/ribavirin (IFN/RBV)"><entity charOffset="157-166" id="DDI-PubMed.23701022.s4.e0" text="ribavirin" /></sentence><sentence text=" To further investigate this observation, we retrospectively reviewed 61 HIV/HCV-coinfected patients on antiretrovirals (ARVs) during treatment with IFN/RBV as well as 154 HIV-infected patients treated with ARVs alone" /><sentence text=" We found that HIV/HCV-coinfected patients on IFN/RBV therapy were more likely to develop frequent (57% vs" /><sentence text=" 13%, IFN/RBV-treated patients vs" /><sentence text=" no IFN/RBV; χ(2)=0" /><sentence text="001) and higher-grade hypophosphatemia (67" /><sentence text="0% Grade 2, 33" /><sentence text="3% Grade 3 vs" /><sentence text=" 94" /><sentence text="7% Grade 2, 5" /><sentence text="3% Grade 3, IFN/RBV-treated patients vs" /><sentence text=" no IFN/RBV; χ(2)&lt;0" /><sentence text="001) than untreated patients" /><sentence text=" In addition, we found that the new onset of hypophosphatemia after IFN/RBV treatment initiation was followed by a diminished frequency of this toxicity upon cessation of IFN/RBV, supporting the idea that a drug-drug interaction may increase the risk of this toxicity" /><sentence text=" To understand the risks of developing this toxicity, we evaluated the association between individual ARV use and hypophosphatemia incidence" /><sentence text=" Our data suggest that concomitant tenofovir (TDF) use may be a risk factor for the development of hypophosphatemia in HIV/HCV-coinfected patients treated with IFN/RBV"><entity charOffset="35-44" id="DDI-PubMed.23701022.s19.e0" text="tenofovir" /><entity charOffset="46-49" id="DDI-PubMed.23701022.s19.e1" text="TDF" /><pair ddi="false" e1="DDI-PubMed.23701022.s19.e0" e2="DDI-PubMed.23701022.s19.e0" /><pair ddi="false" e1="DDI-PubMed.23701022.s19.e0" e2="DDI-PubMed.23701022.s19.e1" /></sentence><sentence text=" Although the etiology of this abnormality is likely multifactorial, clinicians should be aware of hypophosphatemia as a potential marker of renal toxicity in HIV/HCV-coinfected patients being treated with IFN/RBV regimens" /><sentence text="" /></document>